Cancer-Associated Mutations Are Common in Patients with Unexplained Low Blood Counts
Patients with unexplained low blood counts and abnormally mutated cells who do not fit the diagnostic criteria for recognized blood cancers should be described as having clonal cytopenias of undetermined significance (CCUS), suggest University of California, San Diego School of Medicine researchers in a recent paper published in the journal Blood. The researchers found the condition surprisingly common in older patients with low blood counts. • Image(s) embedded •
– University of California, San Diego Health Sciences
Study: Only 1 in 5 US Pancreatic Cancer Patients Get This Key Blood Test at Diagnosis
Only 1 in 5 U.S. pancreatic cancer patients receive a widely available, inexpensive blood test at diagnosis that can help predict whether they are likely to have a better or worse outcome than average and guide treatment accordingly, a Mayo Clinic study shows.
Western Surgical Association
– Mayo Clinic
Wistar Scientists Show How a Frequently Mutated Gene in Prostate Cancer Acts as a Tumor Suppressor
The gene SPOP is mutated in up to 15 percent of all cases of prostate cancer, making it one of the most mutated genes in the disease. However, when the gene is functioning properly, it acts as a tumor suppressor. Despite what’s known about SPOP, scientists have not been able to determine exactly how the gene is able to halt the progression of disease. Now, new research from The Wistar Institute has found how SPOP is able to halt tumors by inducing senescence, a state of stable cell cycle arrest, which means that the cells have stopped dividing and growing. With this new information, scientists may be able to design therapeutic strategies that can halt cancers caused by these mutated genes that are able to bypass senescence.
Cell Reports, Oct-2015; R01CA16033; R01CA16337 ; CA010815
– Wistar Institute
An Aggressive Treatment for an Aggressive Cancer
Pancreas cancer remains one of the deadliest cancers worldwide. In the United States, it accounts for only three percent of all diagnosed cancers but it causes almost seven percent of all cancer deaths. A pancreas cancer diagnosis often comes after age 50 and after the cancer has spread, making it difficult to remove surgically. A new clinical trial that recently opened at the University of New Mexico Comprehensive Cancer Center may help more people to undergo surgery to remove their pancreas tumors. And that may help more of them to live longer.
– University of New Mexico Comprehensive Cancer Center
Cancer Cells Hijack Glucose, Alter Immune Cells
When cancer cells compete with immune cells for glucose, the cancer wins. As a result, the immune T cells are not healthy and don’t have the weapons to kill the cancer. (Embargo expired on 02-Nov-2015 at 11:00 ET)
Nature Immunology; CA123088; CA099985; CA156685; CA171306 ; 5P30CA46592
– University of Michigan Health System
Conventional Heart Drug Stops the Progression of Cancer
A common heart drug may stop the progression of angiosarcoma, a cancer of the inner lining of blood vessels, according to a study by researchers at Texas Tech University Health Sciences Center (TTUHSC) El Paso. • Image(s) embedded •
– Texas Tech University Health Sciences Center El Paso
Study Finds That the Crocetinic Acid in Saffron May Inhibit the Pancreatic Cancer Cell Growth
A team of researchers led by KU Cancer Center Cancer Prevention & Survivorship Program member, Animesh Dhar, Ph.D., found that crocetinic acid, a purified compound from crocetin, showed the inhibition of growth in human pancreatic cancer cells grown either in a dish or as tumors under the skin of mice. • Image(s) embedded •
– University of Kansas Cancer Center
Sugar-Coated Nanoworms Not for Breakfast in the Human Immune System
University of Colorado Cancer Center study shows how iron nanoparticles evade human immune system, potentially helping useful particles avoid elimination. • Image(s) embedded •
ACS Nano; R21CA167524-3
– University of Colorado Cancer Center
UCLA Researchers Find a Wide Variation in Costs to
Treat Low-Risk Prostate Cancer
Now, for the first time, UCLA researchers have described cost across an entire care process for low-risk prostate cancer – from the time a patient checks in for his first appointment to his post-treatment follow-up testing - using time-driven activity-based costing. • Image(s) embedded •
– University of California, Los Angeles (UCLA), Health Sciences
Forget Counting Sheep - Therapy Could Help Chronic Pain Sufferers Get a Good Night’s Sleep
Research conducted at the University of Warwick indicates that chronic pain sufferers could benefit from therapy to help them sleep better. • Image(s) embedded • (Embargo expired on 30-Oct-2015 at 15:00 ET)
SLEEP, Vol. 38, No. 11, 2015
– University of Warwick
Mayo Clinic: Cologuard Stool DNA Test Accurate in Screening for Colorectal Cancer in Alaska Native People
Cologuard stool DNA testing for colorectal cancer was found to be an accurate noninvasive screening option for Alaska Native people, a population with one of world’s highest rates of colorectal cancer, concluded researchers from the Alaska Native Tribal Health Consortium and Mayo Clinic.
Mayo Clinic Proceedings
– Mayo Clinic
New Computational Strategy Finds Brain Tumor-Shrinking Molecules
Patients with glioblastoma, a type of malignant brain tumor, usually survive fewer than 15 months following diagnosis. Since there are no effective treatments for the deadly disease, University of California, San Diego researchers developed a new computational strategy to search for molecules that could be developed into glioblastoma drugs. In mouse models of human glioblastoma, one molecule they found shrank the average tumor size by half. The study is published October 30 by Oncotarget. • Image(s) embedded •
– University of California, San Diego Health Sciences
New Immunotherapy Treatment May Clear Cancer-Causing HPV Infections Faster
A new therapeutic vaccine, GTL001, developed by Genticel to clear HPV strains 16 and 18 – the types most likely to cause cancer – is being evaluated for safety in a Phase I clinical trial at the University of Louisville, along with Philadelphia and Columbus, Oh.
– University of Louisville
City of Hope Launches New Campaign to Showcase Innovations in Research and Treatment
Called “The Miracle of Science with Soul,” the new campaign is the first-ever broad communications program by City of Hope, which pioneered the technology behind cancer treatment game-changers trastuzumab (Herceptin®), bevacizumab (Avastin®) and rituximab (Rituxan®), as well as synthetic human insulin for the treatment of diabetes. The campaign is centered around the real stories of six patients who showcase how City of Hope fuses science and research innovation with compassionate care in order to save lives. • Image(s) embedded •
– City of Hope
Immunotherapy for Pancreatic Cancer Boosts Survival by More Than 75% in Mice
A new study in mice by researchers at Fred Hutchinson Cancer Research Center has found that a specialized type of immunotherapy — even when used without chemotherapy or radiation — can boost survival from pancreatic cancer, a nearly almost-lethal disease, by more than 75 percent. The findings are so promising, human clinical trials are planned within the next year. • Image(s) embedded • (Embargo expired on 29-Oct-2015 at 12:00 ET)
Cancer Cell; CA015704; CA018029; CA033084; CA161112
– Fred Hutchinson Cancer Research Center
Timing Is Everything in Cells, Virginia Bioinformatics Institute Researchers Say
The study has implications for cancer research, as scientists try to understand how cells avoid errors that promote cancer development. It could also be useful in synthetic biology, where scientists work to make robust mechanisms for synthetic life. • Image(s) embedded • (Embargo expired on 29-Oct-2015 at 12:00 ET)
– Virginia Tech
TSRI Study Suggests Tumors May ‘Seed’ Cancer Metastases Earlier Than Expected
A study from scientists at The Scripps Research Institute helps explain why cancer metastasis is so hard to stop. The researchers found a mechanism explaining how a molecule linked to cancer progression appears to “seed” the body with metastatic cells long before a primary tumor would be detected.
– Scripps Research Institute
Exercise Could Provide a Margin of Safety for Women Who Want to Delay Preventive Mastectomy
Regular physical activity could play a role in helping women at high-risk of breast cancer delay the need for drastic preventive measures such as prophylactic mastectomy, according to new research led by the Perelman School of Medicine at the University of Pennsylvania. Results of the WISER Sister study help clarify the emerging connection between exercise and breast cancer risk. As a result of the new findings, the authors suggest that women who have an elevated breast cancer risk or worry about having such risk should consider doing 30 to 60 minutes of aerobic activity per day for five days per week.
Breast Cancer Research and Treatment; R01-CA131333; UL1TR000003
– Perelman School of Medicine at the University of Pennsylvania
MD Anderson’s Moon Shots Mission Grows to Confront Six More Cancer Types
MD Anderson’s Moon Shots Program, an unprecedented effort and novel organizational model designed to more rapidly convert scientific discoveries into life-saving advances, has expanded its targets, adding several of the most intractable cancers to its campaign.
– University of Texas M. D. Anderson Cancer Center
Genetic Changes Are Focus of Sanford Breast Cancer Clinical Trial
ELSA enrolling newly diagnosed patients • Image(s) embedded •
– Sanford Health
More than Math: Biostatistics Strengthens Cancer Research
Ji-Hyun Lee, DrPH, leads the Biostatistics team at UNM Comprehensive Cancer Center. "My work helps to improve patient's care," she says. Statistics is the science of collecting, summarizing, analyzing and interpreting data to make decisions. Statisticians help teams of scientists through the entire scientific process; biostatistics applies to health science areas, like cancer.Expert(s) available
– University of New Mexico Comprehensive Cancer Center
FDA Approves Cancer-Killing Cold Sore Virus as Therapy for Late-Stage Melanoma
The U.S. Food and Drug Administration announced on Oct. 27 that it has approved, for the first time, an oncolytic (cancer-killing) viral therapy in the United States. The drug was approved for use against late-stage melanoma, a deadly skin cancer.
Journal of Clinical Oncology
– University of Utah Health Sciences
Viral Therapy in Melanoma Clinical Trial Led by Rutgers Cancer Institute Physician-Scientist is Approved by FDA
The U.S. Food and Drug Administration has approved an immunotherapy known as T-VEC that was the focus of a phase III melanoma clinical trial led by Rutgers Cancer Institute of New Jersey Associate Director for Clinical Science and Chief Surgical Officer Howard L. Kaufman, MD, FACS.
• Image(s) embedded •
– Rutgers Cancer Institute of New Jersey
The Medical Minute: Looking Good to Feel Better During Cancer Treatment
When facing a cancer diagnosis, it can be challenging to keep one’s spirits up. For women, the side effects that treatment may have on their physical appearance can make it difficult to leave the house and face the world.
– Penn State Milton S. Hershey Medical Center
Inherited Gene Variation Linked to an Increased Risk of the Most Common Childhood Cancer
Research led by St. Jude Children’s Research Hospital investigators found evidence that variations in the ETV6 gene may play a significant role in the inherited predisposition to pediatric acute lymphoblastic leukemia. • Image(s) embedded • (Embargo expired on 27-Oct-2015 at 18:30 ET)
CA21765; CA98543; CA114766; CA98413; CA180886; CA180899; GM92666; GM115279; GM115279; GM097119
– St. Jude Children's Research Hospital
3D Organoid Modeling of Pancreatic Cancer May Help Predict Clinical Responses and Personalize Cancer Treatments
A new method to grow 3D organoid cultures of pancreatic tumors directly from patients' surgical tissue offers a promising opportunity for testing targeted therapies and drug responses and personalizing treatments in a rapid, cost-effective manner.
– Beth Israel Deaconess Medical Center
Environment of Tumors Impacts Metastasis, Study Finds
The microenvironment of a tumor cell has significant impact on cancer metastasis, according to a discovery by Siyuan Zhang at the University of Notre Dame and a team at the University of Texas MD Anderson Cancer Center. • Image(s) embedded •
– University of Notre Dame